Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Platinum-resistant Ovarian Cancer
NCT06028932Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Jan 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Yale University. Primary endpoint: Objective Response Rate at 4 years. Started Jan 2024; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06028932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028932.